Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Incidence of blood based deficiencies is strong predictor of poor outcome in pSS patients: Study

Incidence of blood based deficiencies is strong predictor of poor outcome in pSS patients: Study

ASH selects 14 participants for 2010 MMSAP

ASH selects 14 participants for 2010 MMSAP

ASH announces recipients of 2010 ASH Research Training Award for Fellows

ASH announces recipients of 2010 ASH Research Training Award for Fellows

Paternal involvement in pregnancy reduces infant deaths

Paternal involvement in pregnancy reduces infant deaths

FDA approves new indication for Tasigna in treatment of rare blood cancer

FDA approves new indication for Tasigna in treatment of rare blood cancer

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana to treat men with prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

AssureImmune merges with BCU

AssureImmune merges with BCU

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

New research evaluating substantial disease burden of PNH presented at European Hematology Association

New research evaluating substantial disease burden of PNH presented at European Hematology Association

People under 25 contribute 38% of voluntary blood donations

People under 25 contribute 38% of voluntary blood donations

Researchers report 4 pillars of preventive medicine for AD

Researchers report 4 pillars of preventive medicine for AD

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Cubist to oppose Teva’s attempt to add new defense in patent infringement litigation

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

Cell Therapeutics presents data on PIX301 trial of Pixuvri for relapsed or refractory, aggressive NHL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.